Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T11:10:52.426Z.
Calculation as of: 2026-10-06T11:10:52.426Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3b719543d2ad964e34cebd38a4954272106044749b474b483c00e469aab85807
PEG RATIO
N/A
Market Cap
$14.97B
PEG Ratio
N/A
TTM Avg
1.66
3Y Avg
1.31
5Y Avg
1.86
Market Cap
$13.19B
PEG Ratio
N/A
TTM Avg
6.43
3Y Avg
5.04
5Y Avg
3.49
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ascendis Pharma A/S (ASND) | $14.16B | N/A | N/A | N/A | N/A |
| Tempus AI, Inc. (TEM)vs › | $14.64B | N/A | N/A | N/A | N/A |
| Exelixis, Inc. (EXEL)vs › | $14.79B | 0.36 | 0.77 | 5.39 | 7.54 |
| Charles River Laboratories International, Inc. (CRL)vs › | $14.97B | N/A | 1.66 | 1.31 | 1.86 |
| Corcept Therapeutics Incorporated (CORT)vs › | $13.19B | N/A | 6.43 | 5.04 | 3.49 |
| Solventum Corporation (SOLV)vs › | $15.24B | 1.76 | 1.52 | 1.52 | 1.52 |
| BridgeBio Pharma, Inc. (BBIO)vs › | $12.95B | N/A | N/A | N/A | N/A |
| ICON Public Limited Company (ICLR)vs › | $12.89B | N/A | 2.64 | 6.31 | 6.30 |
| Baxter International Inc. (BAX)vs › | $12.52B | N/A | 3.72 | 3.63 | 3.63 |
| Penumbra, Inc. (PEN)vs › | $12.49B | N/A | 4.12 | 4.12 | 4.12 |
PEG Ratio
N/A
P/E Ratio
17.3
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
